Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 14/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.47 |
| ▸ | PDE2A | O00408 | 2/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13865827 | 0.90 | PDE9A (0.47) | PDE9APDE1CPDE1B | |
| SCHEMBL13865839 | 0.86 | TYK2 (0.52) | TSHRMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13865823 | 0.85 | TSHR (0.47) | TSHRMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13865815 | 0.84 | PDE9A (0.57) | PDE9ACYP3A4CYP2C9CYP2C19PDE2A | |
| SCHEMBL13865808 | 0.82 | PDE9A (0.46) | PDE9APDE1CPDE1B | |
| SCHEMBL13865877 | 0.82 | TSHR (0.47) | TSHRMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13866015 | 0.81 | PDE9A (0.64) | PDE9APDE1C | |
| SCHEMBL13865749 | 0.81 | PDE9A (0.54) | PDE9APDE1CPDE1B | |
| SCHEMBL13865759 | 0.81 | PDE9A (0.56) | PDE9APDE1CPDE1B | |
| SCHEMBL13865825 | 0.80 | PDE9A (0.50) | PDE9ATSHRPDE1CHTTPDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | PDE9A 13/4885TSHR 4657/4885PDE1C 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.